Most patients diagnosed with breast cancer have a subtype that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). While this form of breast cancer is generally highly treatable in its earlier stages, some patients will unfortunately develop metastatic disease. However, the treatment landscape for HR+, HER2- metastatic breast cancer has seen significant advancements in recent years, with the introduction of new therapies that improve both quality of life and progression-free survival. These treatment options include endocrine therapies, CDK4/6 inhibitors, and antibody-drug conjugates (ADCs).
This program will cover evidence-based treatment options and treatment selection strategies, the management of treatment-related adverse events, and ways to optimize quality of life for patients with HR+, HER2- metastatic breast cancer. Earn up to 1.5 CE/CME hours.